Liu et al., evaluated the effect of Napabucasin, a small STAT3 inhibitor, and found that it attenuates BC cell resistance to TAM by reducing the population of BCSCs, which was evidenced by the decrease in stem markers (OCT4, NANOG, and SOX2), in combination with a reduction in the ability to form spheroids and a decrease of the ALDH1 activity [91]. Here, STAT3 is linked to breast cancer.